home / stock / srne / srne news

SRNE News and Press, Sorrento Therapeutics Inc. From 05/02/22

Stock Information
Company Name: Sorrento Therapeutics Inc.
Stock Symbol: SRNE
Market: NASDAQ
Website: sorrentotherapeutics.com
Menu
SRNE SRNE Quote SRNE Short SRNE News SRNE Articles SRNE Message Board
Get SRNE Alerts

News, Short Squeeze, Breakout and More Instantly...
SRNE - Sorrento Announces Full Enrollment of Phase I Study of Intranasal STI-9199 (COVISHIELD(TM) IN), a Potent Neutralization Antibody Against Omicron BA.2 and All Variants of Concern

The Phase I safety and pharmacokinetic study in 24 healthy volunteers has completed enrollment. The study is still blinded, but only 5 minor adverse events requiring no treatment have been reported in the entire study to date, similar to the safety profile observed in Sorrento’s CO...
SRNE - Scilex, part of Sorrento Therapeutics names new CFO

Scilex, a nearly 100% majority-owned subsidiary of Sorrento Therapeutics (NASDAQ:SRNE -3.2%) announced that Elizabeth Czerepak will join the company as executive VP, CFO and Chief Business Officer, effective May 18, 2022.  Ms. Czerepak will be a member of the Scilex a...

SRNE - Scilex Holding Company a Majority-Owned Subsidiary of Sorrento Therapeutics, Inc., Appoints Highly Accomplished Life Science Executive, Elizabeth Czerepak, as Executive Vice President, Chief Financial Officer (CFO) and Chief Business Officer (CBO)

SAN DIEGO and PALO ALTO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), who is a commercial biopharmaceutical company...

SRNE - Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., to Present SP-102 (SEMDEXA(TM)) Efficacy and Safety Data from its Pivotal Phase 3 Clinical Trial Program for Sciatica Pain Management at the 24th Annual Meeting of America

PALO ALTO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused on developin...
SRNE - Celularity: Funds Infusion Needed ASAP To Advance

Celularity posted revenue of $21.3M and diluted EPS of -$1.49 for FY-2021. The Company received five FDA fast track/orphan-drug destinations in FY-2021 for its lead candidates. The stock price is up 38%+ since our last coverage in September 2021, however, the company is in need of...

SRNE - Sorrento subsidiary Scilex expands distribution network to national, regional wholesalers

Scilex Holding Co., a subsidiary of Sorrento Therapeutics (NASDAQ:SRNE), is expanding its direct distribution network to national and regional wholesalers and pharmacies. Scilex said the move gives it better control over distribution of its lidocaine patch Ztildo and to launch future products...

SRNE - Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Expanding Its Direct Distribution Network to National And Regional Wholesalers And Pharmacies

PALO ALTO, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused on developin...
SRNE - Sorrento gets FDA nod to start early-stage trial for intravenous COVID-19 therapy

Sorrento Therapeutics (NASDAQ:SRNE) announced on Monday that the U.S. Food and Drug Administration (FDA) cleared its investigational new drug application (IND) to study intravenous STI-9167 (COVISHIELD) in healthy volunteers. The Phase 1 study will proceed at a single trial site in the U.S., ...

SRNE - Sorrento Announces FDA Authorization to Proceed with Phase 1 Study of Intravenous STI-9167 (COVISHIELD), a Potent Neutralization Antibody Against Omicron BA.2 and Other SARS-CoV-2 Variants of Concern

FDA granted IND clearance today for STI-9167 (Intravenous COVISHIELD™) for a Phase 1 safety and pharmacokinetic study in healthy volunteers. Initial trials are expected to be followed by a multinational Phase 2/3 trial in both mild and moderate COVID-19 patients. STI-9167 h...

SRNE - Dr. Henry Ji, Sorrento Therapeutics' Chairman and CEO and Scilex Holding Company's Executive Chairman, to Present at the B. Riley Securities' 2022 Virtual Neuro & Opthalmology Healthcare Conference (April 27-28, 2022)

SAN DIEGO and PALO ALTO, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento”) today announced that Dr. Henry Ji, Chairman and CEO of Sorrento and Executive Chairman of Scilex Holding Company (“Scilex”), will participat...
Previous 10 Next 10